Pharma Major Novartis Falls Nearly 10%, Heading for Worst Day on Record After Three Drug Trial Setbacks in a Week
Novartis shares tanked as much as 10.6 percent in Tuesday trading, putting the Swiss pharmaceutical giant on track for its worst single trading day on record after the company disclosed its third significant drug trial disappointment within seven days. The latest blow came from del-desiran, an experimental therapy for a rare, progressive muscle-wasting condition, and … Read more